BAJAJ BROKING

Notification close image
No new Notification messages
card image
Seshaasai Technologies Ltd IPO
Apply for the Seshaasai Technologies Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

Diwali Stock Pick | Senores Pharmaceuticals Ltd | Bajaj Broking Research Desk

Synopsis:


Senores Pharmaceuticals has emerged as a promising name in the healthcare space this festive season. With new USFDA approvals, strategic acquisitions, and an expanding manufacturing base, the company looks poised for steady growth across key markets.

About the Company

Senores Pharmaceuticals Ltd is an established player in the global generics market, now gaining fresh momentum.

Based in India, the company targets regulated markets such as the US and Canada, along with select emerging regions. Its USFDA-approved plants in India and the US have a strong compliance record.

Since its late-2024 listing, Senores has grown rapidly by filing new products, expanding capacity, and acquiring assets. Led by an experienced team, the company continues to focus on growth through filings, expansion, and strategic mergers.

Field

Detail

NSE / BSE

SENORES / 544319

Bloomberg Code

SENORES:IN

CMP (₹)

720

Target (₹)

832

Upside

16%

52W High / Low (₹)

751 / 435

Market Cap (₹)

33.08 bn

Promoter Pledge (01-10-2025)

10.89%

SENORES PHARMACEUTICALS L

Trade

714.85.79 (0.81 %)

Updated - 08 October 2025
717.75day high
DAY HIGH
700.75day low
DAY LOW
156092
VOLUME (BSE)

Robust ANDA Approvals Setting the Stage

The last twelve months have been crucial. Senores secured several key USFDA approvals, including Metoprolol Tartrate and Hydrochlorothiazide Tablets and Tramadol.

These launches will help the company tap high-value opportunities in the US market. According to management, H2FY26 should mark the start of a steady revenue ramp-up in the US as these products roll out.

Acquisitions Driving Monetization Ahead

Growth isn’t just coming from approvals; acquisitions are adding another layer.
Senores recently bought 14 approved ANDAs from Dr. Reddy’s Laboratories, along with select portfolios from other US sellers.

The plan is to commercialize these products in a phased manner from H2FY26. Once integrated, these launches are expected to widen Senores’ US addressable market and lift revenue visibility.

Emerging Markets – The Hidden Catalyst

In FY25, the Emerging Market (EM) segment made up around 30% of total revenue.
But this part of the business is being re-engineered.

The company is shifting toward niche molecules and tapping into a broader network of distributors. This new mix is likely to double per-unit realizations  improving both growth and profitability in the EM division.

Capex – Investing for Tomorrow

Senores is actively building its US foundation. In early 2025, it invested USD 1.99 million in its wholly owned US arm, Senores Pharmaceuticals Inc., through a rights issue.

The capital supports working capital and helps grow the company’s ANDA pipeline and IP portfolio all aligned with its IPO commitments.

At the same time, the company is doubling its manufacturing strength in Atlanta, expanding annual capacity to 2 billion units.
Two new oral solid lines are being installed, one expected to be ready by Q3FY26, the other by end-FY26.

A sterile injectables department will follow in FY27, helping Senores serve a bigger base of global customers.

Backward Integration to increase Margins

To strengthen profitability, Senores is expanding its API manufacturing base in Gujarat.

This strategy ensures better control over input costs and improves fixed-cost absorption.

Management expects this to result in a visible improvement in EBITDA margins from the next fiscal year. The combination of in-house API and integrated manufacturing should support long-term margin stability.

Valuation

Senores stands on a well-defined growth path.

Its USFDA-approved portfolio, strategic ANDA acquisitions, and growing manufacturing lines underline a solid foundation for the next few years.

The company has been valued at ₹832 per share, based on a P/E multiple of 30× FY27E earnings. The figure displays its high-quality product pipeline, efficient cost structure, and ongoing capacity expansion.

Conclusion

Senores Pharmaceuticals represents an all rounder Diwali stock pick this year.

With new approvals, expanded capacity, and backward integration underway, the company is stepping into its next growth phase.

Its focus on the US market, along with higher-margin emerging market operations, gives it both stability and scale making it a chosen pick for this festive season.

Read More Blogs

Disclaimer :

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

11 lakh+ Users

icon-with-text

4.6 App Rating

icon-with-text

4 Languages

icon-with-text

₹6,800+ Cr MTF Book

icon-with-text